title: Rationale for the use of radiolabelled peptides in diagnosis and therapy.
abstract: Nuclear medicine techniques are becoming more important in imaging oncological and infectious diseases. For metabolic imaging of these diseases, antibody and peptide imaging are currently used. In recent years peptide imaging has become important, therefore the rationale for the use of peptide imaging is described in this article. Criteria for a successful peptide tracer are a high target specificity, a high binding affinity, a long metabolic stability and a high target-to-background ratio. Tracer internalization is also beneficial. For oncological imaging, many tracers are available, most originating from regulatory peptides, but penetrating peptides are also being developed. Peptides for imaging inflammatory and infectious diseases include regulatory peptides, antimicrobial peptides and others. In conclusion, for the imaging of oncological, imflammatory and infectious diseases, many promising peptides are being developed. The ideal peptide probe is characterized by rapid and specific target localization and binding with a high tumour-to-background ratio.
authors.affiliation: Department of Radiology and Nuclear Medicine, Martini Hospital, Van Swietenplein 1, 9728 NT Groningen, The Netherlands. k.koopmans@mzh.nl
authors.forename: K P
authors.initials: KP
authors.lastname: Koopmans
authors.forename: A W J M
authors.initials: AW
authors.lastname: Glaudemans
mesh_terms: D023181:Antimicrobial Cationic Peptides; D001839:Bombesin; D002766:Cholecystokinin / Q000031:analogs & derivatives; D019886:Gastrin-Releasing Peptide; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007239:Infections / Q000000981:diagnostic imaging; D007249:Inflammation / Q000000981:diagnostic imaging; D007553:Isotope Labeling; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D010455:Peptides / Q000627:therapeutic use*; D011877:Radionuclide Imaging / Q000379:methods / Q000639:trends; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives; D014660:Vasoactive Intestinal Peptide
chemical_list: D023181:Antimicrobial Cationic Peptides; D010455:Peptides; D019275:Radiopharmaceuticals; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D019886:Gastrin-Releasing Peptide; D052216:Glucagon-Like Peptide 1; D002766:Cholecystokinin; D001839:Bombesin